A Phase 3B Randomized Study Of Lenalidomide (Cc-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance In Subjects With Relapsed/Refractory Follicular,Marginal Zone Or Mantle Cell Lymphoma
Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are
distinct histologic types of B-cell NHL. Lenalidomide is an immunomodulatory agent with
direct and immune-mediated mechanisms of action, as well as clinical activity in NHL. Recent
studies in frontline and relapsed/refractory NHL show high activity for lenalidomide plus
rituximab (R2), supporting further study of this combination.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.